Newron Pharmaceuticals S.p.A. (NWRN.SW)
Swiss · CHF · Healthcare · Biotechnology
CHF 8.85 (-2.75%) as of
Key statistics
- Market cap
- 180.96M
- Forward P/E
- 16.13
- EPS (TTM)
- -1.35
- Dividend yield
- 0.00%
- 52-week range
- 5.72 – 31.85
- Beta
- 0.85
- Revenue (TTM)
- 10.42M
- Profit margin
- -283.56%
- Analyst target
- CHF 38.03
- Volume
- 34.08k
About Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. It has a strategic partnership with Zambon and Meiji Seika Pharma Co., Ltd. for the commercialization of safinamide. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Bresso, MI, Italy
- Employees
- 27
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.